Reports on Project BioShield; Working to Defend Against Bioterrorism through a

Published: Fri Nov 04 2005 Reports on Project BioShield; Working to Defend Against Bioterrorism through a Stronger Biodefense Arena
Threat of Avian Flu Pandemic Escalates Need for Biological Countermeasures
POINT ROBERTS, WA.; November 4, 2005 - (BDS), and (HDS), investor news portals for the Biodefense and Homeland Security sectors, report on the growth of the biodefense arena in light of the challenges and opportunities realized through Project BioShield. Punk, Ziegel & Company’s Senior Biotechnology Analyst, Sharon Seiler provides perspective on the current environment under BioShield, while Hollis-Eden Pharmaceuticals, Inc. (NASDQ: HEPH), VaxGen Inc. (OTC.PK: VXGN), Aethlon Medical, Inc. (OTCBB: AEMD) and Acambis plc (LSE: ACM) reveal industry insights.
Report Excerpt: Project BioShield – Challenging and Strengthening the Biodefense Arena
By Ann-Marie Fleming,,
November 2005
Since the attacks of 9-11 the U.S. Government has injected considerable funds into the biodefense arena for the development and production of countermeasures against potential biological threats. With current fears of a possible avian flu pandemic, in addition to bioterrorist concerns, the issue of biosecurity has been readdressed. One of the main government initiatives is Project BioShield, which was signed into law in July 2004 to help spark participation in biodefense from the private sector, and in particular from biotechnology and pharmaceutical companies.
"The goal of Project BioShield is to converge the government’s intent to purchase with the ability of the capital markets to fund. Those companies, who effectively advance their treatment countermeasure from a regulatory standpoint, should expect the government to acquire that treatment for the national stockpile. This reality provides significant incentive for the capital markets to infuse the equity resources that will drive the countermeasures into the marketplace. It should be noted that the pathogens of greatest concern do not allow for human efficacy studies for obvious humanitarian reasons. So in essence, you have an abbreviated regulatory path with a back-end guarantee to purchase," stated James A. Joyce, CEO of Aethlon Medical, Inc, a developer of the first medical devices to treat infectious diseases, including several Class "A" biological weapon threats.
The advantages that accompany Project BioShield, however are not without its challenges. The process of distribution of advanced contracts remains an area of controversy as the timing and somewhat unclear parameters do not always provide the opportunity that the program initially suggested, discussed Robert Marsella, Senior Vice President of Hollis-Eden Pharmaceuticals.

Concerns surrounding issues of liability protection continue to create uncertainty and are considered critical to encouraging pharmaceutical companies to participate in the program, explained Paul Laland, Vice President, Public Affairs for VaxGen, Inc.

To Read the Full Report Click Here:

To Listen to a Recent Audio Interview with James Joyce, CEO of Aethlon Medical Inc. on the subject of Project BioShield and the Company’s Hempurifier™ as a countermeasure against infectious diseases and toxins in the body – Click Here:

The BDS and HDS Websites do not make recommendations, but offer unique information portals for investors to explore news, articles, and recent research.

Featured Company: (BDS and HDS are compensated as disclosed in disclaimer)

Aethlon Medical, Inc (OTCBB: AEMD) is pioneering the development of therapeutic devices that mimic the immune response of clearing viruses and viral toxins from circulation. The Company’s lead product, the HemopurifierTM, converges the established principals of hemodialysis and affinity chromatography with the discovery of compounds that effectively adhere to the surface of a multiple envelope viruses. The HemopurifierTM is targeted to treat acute and chronic infectious diseases, including, drug and vaccine resistant Biological Weapons, the Human Immunodeficiency Virus (HIV), and the Hepatitis-C Virus (HCV). The Company has an experienced management team, which receives support and guidance from globally recognized science and regulatory advisors representing the infectious disease, biowarfare, and dialysis industries.

For more information on Aethlon Medical, click here:, a portal within the and content umbrella, offers investors research, news and links to public companies within the biodefense industry. For a list of companies within this sector: includes a growing list of public companies in the defense and security sector. Click here for a partial list of companies involved in homeland defense and security technology:

Member: US National Defense Industries Association (NDIA), Canadian Defence Industries Association (CDIA) Blog:
Read the latest news and views about the Homeland Defense Industry and Homeland Security Stocks: or

Homeland Security / Advertising Opportunities: RSS Feeds and Blogs: /RSS/Default.asp

Investor Incite Newsletter’s free "Investor Incite" Newsletter consists of company and industry updates, investment research and developing trends in key areas such as Homeland Security, Renewable Energy, Oil and Gas and more.

TO SIGN UP, click here: Disclaimer: Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. The site is currently compensated for by its "featured companies." Aethlon Medical, Inc. (OTCBB: AEMD) Three thousand dollars per month, plus restricted shares equivalent to five thousand dollars per month.

For more information contact:
Dawn Van Zant 800.665.0411
Ann-Marie Fleming 866.725.2554
Email:, or

Contact Name: Anne-Marie Fleming
Contact Email:
Contact Phone: 866-725-2554

Visit website »